Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide

被引:14
作者
Huang, TS
Lee, SSJ
Tu, HZ
Huang, WK
Chen, YS
Huang, CK
Wann, SR
Lin, HH
Liu, YC
机构
[1] Kaohsiung Vet Gen Hosp, Sect Microbiol & Infect Dis, Kaohsiung, Taiwan
[2] Foo Yin Inst Technol, Dept Med Technol, Kaohsiung, Taiwan
[3] Natl Yang Ming Univ, Dept Med, Taipei 112, Taiwan
关键词
minimum inhibitory concentration; M; tuberculosis; susceptibility testing;
D O I
10.1093/jac/dkh120
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Tentative standards for testing MICs for Mycobacterium tuberculosis include agar dilution and the BACTEC method. However, the conventional agar dilution method requires 3-5 weeks to complete; whereas BACTEC, although a rapid test, involves the use of radioisotopes. In contrast, the MGIT 960 system uses a fluorescence quenching based oxygen sensor that can be read automatically. This system is not only robust, safe and simple, but has been validated for susceptibility tests of first-line antituberculous agents. Methods: We evaluated 46 clinical strains of M. tuberculosis isolated from patients admitted to Kaohsiung Veterans General Hospital. Testing of MICs of ciprofloxacin and ethionamide was carried out by MGIT 960 and compared with the agar dilution method. Results: Good agreement was found between MGIT 960 and agar dilution. The greatest concordance between the agar dilution and MGIT assay at +/-1 and +/-2 dilution was 80.4% and 97.8% for ciprofloxacin, and 82.6% and 93.5% for ethionamide, respectively. Conclusion: MGIT 960 was found to be comparable to the current NCCLS standard method, agar dilution, and has the advantage of being rapid (obtaining results within 5-17 days, average 8.9 days) and easy to achieve standardization.
引用
收藏
页码:600 / 603
页数:4
相关论文
共 20 条
  • [1] AMIKACIN IN THE TREATMENT OF PULMONARY TUBERCULOSIS
    ALLEN, BW
    MITCHISON, DA
    CHAN, YC
    YEW, WW
    ALLAN, WGL
    GIRLING, DJ
    [J]. TUBERCLE, 1983, 64 (02): : 111 - 118
  • [2] TUBERCULOSIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    BARNES, PF
    BLOCH, AB
    DAVIDSON, PT
    SNIDER, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (23) : 1644 - 1650
  • [3] Kanamycin susceptibility testing of Mycobacterium tuberculosis using mycobacterium growth indicator tube and a colorimetric method
    Bastian, I
    Rigouts, L
    Palomino, JC
    Portaels, F
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1934 - 1936
  • [4] Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis
    Bemer, P
    Palicova, F
    Rüsch-Gerdes, S
    Drugeon, HB
    Pfyffer, GE
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (01) : 150 - 154
  • [5] TUBERCULOSIS AND HUMAN IMMUNODEFICIENCY VIRUS-INFECTION
    CHAISSON, RE
    SLUTKIN, G
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (01) : 96 - 100
  • [6] Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay
    Franzblau, SG
    Witzig, RS
    McLaughlin, JC
    Torres, P
    Madico, G
    Hernandez, A
    Degnan, MT
    Cook, MB
    Quenzer, VK
    Ferguson, RM
    Gilman, RH
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (02) : 362 - 366
  • [7] Evaluation of mycobacteria growth indicator tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital
    Goloubeva, V
    Lecocq, M
    Lassowsky, P
    Matthys, F
    Portaels, F
    Bastian, I
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (04) : 1501 - 1505
  • [8] Heifets L, 2000, RESURG EMERGING INFE, V1, P133
  • [9] HEIFETS LB, 1991, DRUG SUSCEPTIBILITY, P97
  • [10] Huang TS, 2002, ANN CLIN LAB SCI, V32, P142